{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:10:34Z","timestamp":1791389434104,"version":"4.3.3"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ejca.2018.07.129","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T14:21:05Z","timestamp":1536243665000},"page":"7-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"special_numbering":"C","title":["Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"103","author":[{"given":"Fausto","family":"Petrelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Ardito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Borgonovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Lonati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Cabiddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Ghilardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Barni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.07.129_bib1","series-title":"Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers\u202f: a meta-analysis","first-page":"141","author":"Man","year":"2018"},{"issue":"11","key":"10.1016\/j.ejca.2018.07.129_bib2","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ejca.2018.07.129_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1016\/j.ejca.2018.07.129_bib4","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.07.129_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"ScienceDirect Immune-related adverse events with immune checkpoint blockade\u202f: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2018.07.129_bib6","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/CJI.0b013e31819aa40b","article-title":"Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 Antibody)","volume":"32","author":"Akhtari","year":"2009","journal-title":"J Immunother"},{"issue":"11","key":"10.1016\/j.ejca.2018.07.129_bib7","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.ejca.2018.07.129_bib8","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating Characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.ejca.2018.07.129_bib9","first-page":"1","article-title":"Bias in meta - analysis detected by a simple , graphical test","volume":"14","author":"Egger","year":"2015","journal-title":"BMJ"},{"issue":"10027","key":"10.1016\/j.ejca.2018.07.129_bib10","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2018.07.129_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.07.129_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2017.07.022","article-title":"Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma","volume":"86","author":"Hamid","year":"2017","journal-title":"Eur J Cancer"},{"issue":"10064","key":"10.1016\/j.ejca.2018.07.129_bib13","first-page":"67","volume":"389","author":"Balar","year":"2017","journal-title":"HHS Public Access"},{"key":"10.1016\/j.ejca.2018.07.129_bib14","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ejca.2018.07.129_bib15","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2018.07.129_bib16","first-page":"444","volume":"8","author":"Long","year":"2016","journal-title":"HHS Public Access"},{"issue":"11","key":"10.1016\/j.ejca.2018.07.129_bib17","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","article-title":"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial","volume":"17","author":"Sharma","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2018.07.129_bib18","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ejca.2018.07.129_bib19","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ejca.2018.07.129_bib20","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","article-title":"Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study","volume":"35","author":"Bauml","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9948","key":"10.1016\/j.ejca.2018.07.129_bib21","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ejca.2018.07.129_bib22","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2018.07.129_bib23","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00280-016-3237-x","article-title":"Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)","volume":"79","author":"Yamazaki","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.ejca.2018.07.129_bib24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2018.07.129_bib25","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2018.07.129_bib26","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2018.07.129_bib27","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2014.58.1041","article-title":"Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab","volume":"33","author":"McDermott","year":"2015","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2018.07.129_bib28","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2018.07.129_bib29","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2018.07.129_bib30","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ejca.2018.07.129_bib31","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib keynote-012 study","volume":"34","author":"Nanda","year":"2016","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.ejca.2018.07.129_bib32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.73.3675","article-title":"Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1\u2013positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study","volume":"35","author":"Hsu","year":"2017","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2018.07.129_bib33","first-page":"1","article-title":"Safety and ef fi cacy of pembrolizumab in advanced , programmed death ligand 1 \u2013 positive cervical Cancer\u202f: results from the phase Ib KEYNOTE-028","volume":"35","author":"Frenel","year":"2017","journal-title":"Trial"},{"issue":"7528","key":"10.1016\/j.ejca.2018.07.129_bib34","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.ejca.2018.07.129_bib35","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","article-title":"Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study","volume":"34","author":"McDermott","year":"2016","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.ejca.2018.07.129_bib36","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1200\/JCO.2017.72.5069","article-title":"Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2018.07.129_bib37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2018.07.129_bib38","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2018.07.129_bib39","doi-asserted-by":"crossref","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2018.07.129_bib40","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-l1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ejca.2018.07.129_bib41","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non\u2013small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"issue":"10088","key":"10.1016\/j.ejca.2018.07.129_bib42","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.ejca.2018.07.129_bib43","first-page":"1","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"6736","author":"Powles","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2018.07.129_bib44","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.07.129_bib45","series-title":"Supplementary Appendix","author":"Jr","year":"2012"},{"issue":"21","key":"10.1016\/j.ejca.2018.07.129_bib46","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2018.07.129_bib47","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (Anti\u2013PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2018.07.129_bib48","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"36","key":"10.1016\/j.ejca.2018.07.129_bib49","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1\u2013positive cervical cancer: results from the phase Ib KEYNOTE-028 trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10030","key":"10.1016\/j.ejca.2018.07.129_bib50","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"issue":"34","key":"10.1016\/j.ejca.2018.07.129_bib51","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of Anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2018.07.129_bib52","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2018.07.129_bib53","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(17)30240-1","article-title":"Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial","volume":"18","author":"Gulley","year":"2017","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2018.07.129_bib54","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Data supplement","volume":"33","author":"Gettinger","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2018.07.129_bib55","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2018.07.129_bib56","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2018.07.129_bib57","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2012-0024","article-title":"The risk for anemia with targeted therapies for solid tumors","volume":"17","author":"Barni","year":"2012","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.ejca.2018.07.129_bib58","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/annonc\/mdv182","article-title":"A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors","volume":"26","author":"Chen","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2018.07.129_bib59","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-l1 inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2018.07.129_bib60","first-page":"20","article-title":"Immune thrombocytopenia exacerbated by nivolumab in a patient with non-small-cell lung cancer","volume":"6","author":"Bagley","year":"2016","journal-title":"Cancer Treat Commun"},{"issue":"2","key":"10.1016\/j.ejca.2018.07.129_bib61","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/CMR.0000000000000232","article-title":"Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma","volume":"26","author":"Kong","year":"2016","journal-title":"Melanoma Res"},{"issue":"4","key":"10.1016\/j.ejca.2018.07.129_bib62","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.07.129_bib63","first-page":"638","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"77","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.07.129_bib64","series-title":"Safety and tolerability of PD-1\/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis","first-page":"470","author":"Management","year":"2017"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918311079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918311079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:22:14Z","timestamp":1760732534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918311079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":64,"alternative-id":["S0959804918311079"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.07.129","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.07.129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}